CMS Cuts 2027 Office Reimbursement for Ultramist Code 21% to $314.54
SNWV sits 46% above its 52-week low of $3.92.
Summary
CMS set the 2027 Medicare physician-office rate for CPT 97610, the code covering Sanuwave's Ultramist therapy, at $314.54 per treatment, down about 21% from $397.81 this year. That is the setting where most of the company's treatments are delivered, so the cut hits revenue per procedure directly. There is a partial offset: the hospital outpatient rate rises about 15% to $235.04, and 97610 moves from Q1 to T status in the HOPD setting, allowing separate payment under S, T or V codes. Sanuwave says it is evaluating options and engaging CMS, but any change would require further CMS action and no outcome is assured. The company also expects the office rate could fall again in 2028 once the full phase-in of practice expense RVUs applies, though the 2028 conversion factor is not yet set. This lands on a balance sheet already under strain — a Nasdaq delisting notice in September over the $50M market value requirement and a JPMorgan covenant waiver in October.
At the time of this announcement, SNWV was trading at $5.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $49.3M. The 52-week trading range was $3.92 to $36.20. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.